Production (Stage)
CervoMed Inc.
CRVO
$7.26
$0.141.97%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -18.31% | -13.19% | 27.08% | 91.23% | 66.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -18.31% | -13.19% | 27.08% | 91.23% | 66.72% |
| Cost of Revenue | 71.90% | 148.18% | 186.08% | -- | 53.51% |
| Gross Profit | -525.33% | -1,249.95% | -1,102.00% | 91.23% | -9.78% |
| SG&A Expenses | 11.97% | 9.48% | -8.27% | 153.04% | 112.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 46.10% | 89.15% | 74.60% | 112.96% | 74.38% |
| Operating Income | -104.36% | -191.91% | -101.72% | -143.31% | -81.93% |
| Income Before Tax | -94.65% | -183.86% | -321.05% | -62.53% | -370.58% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -94.65% | -183.86% | -321.05% | -62.53% | -370.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -94.65% | -183.86% | -321.05% | -62.53% | -370.58% |
| EBIT | -104.36% | -191.91% | -101.72% | -143.31% | -81.93% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -38.01% | -104.38% | -184.03% | 90.32% | 60.49% |
| Normalized Basic EPS | -38.01% | -104.37% | -184.05% | 90.32% | 60.48% |
| EPS Diluted | -38.01% | -104.38% | 21.17% | 90.32% | 60.49% |
| Normalized Diluted EPS | -38.01% | -104.37% | -195.68% | 90.32% | 60.48% |
| Average Basic Shares Outstanding | 41.04% | 38.86% | 163.06% | 1,579.75% | 1,090.99% |
| Average Diluted Shares Outstanding | 41.04% | 38.86% | 131.05% | 1,579.75% | 1,090.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |